Abdominal Aortic Aneurysm
Top Cited Papers
- 1 December 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 26 (12), 2605-2613
- https://doi.org/10.1161/01.atv.0000245819.32762.cb
Abstract
Abdominal aortic aneurysm (AAA) affects approximately 5% of elderly men and is responsible for a significant number of deaths in Western Countries. At present surgery by open or endovascular means is the only widely used therapy for this condition. In this review we examine the risk factors, serum, and genetic associations of AAA. Epidemiology studies suggest that smoking cessation and control of cholesterol and blood pressure should reduce the number of patients developing AAA. Natural history studies suggest that smoking cessation should reduce the rate of progression of AAA. Clear level 1 evidence for drug treatments of AAA are presently lacking; however, animal and human in vitro studies suggest that medication targeted at reducing inflammation and proteolysis are most likely to be beneficial, with limited data to support the use of statins, Angiotensin II inhibitors, and macrolides. Work has commenced in understanding which patients, identified by clinical, serum, and genotype, are more at risk of AA... Abdominal aortic aneurysm is associated with significant morbidity and mortality. Presently medical therapy for this condition has been neglected. This article summarises efforts to better understand the pathology of AAA to develop such treatments.Keywords
This publication has 111 references indexed in Scilit:
- Selective Cyclooxygenase-2 Inhibition With Celecoxib Decreases Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- A haplotype map of the human genomeNature, 2005
- Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cellsAtherosclerosis, 2005
- Aminoterminal Propeptide of Type III Procollagen and Matrix Metalloproteinases-2 and -9 Failed to Serve as Serum Markers for Abdominal Aortic AneurysmEuropean Journal of Vascular and Endovascular Surgery, 2005
- Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-κBJournal of Vascular Surgery, 2005
- Risk of cardiovascular events and rofecoxib: cumulative meta-analysisThe Lancet, 2004
- Are antihypertensive drugs associated with abdominal aortic aneurysms?Journal of Vascular Surgery, 2002
- Smoking, but not Lipids, Lipoprotein (a) and Antibodies Against Oxidised LDL, is Correlated to the Expansion of Abdominal Aortic AneurysmsEuropean Journal of Vascular and Endovascular Surgery, 2001
- The Association Between Connective Tissue Laxity and the Risk of an Abdominal Aortic AneurysmEuropean Journal of Vascular and Endovascular Surgery, 2000
- The Plasma Level of Matrix Metalloproteinase 9 may Predict the Natural History of Small Abdominal Aortic Aneurysms. A Preliminary StudyEuropean Journal of Vascular and Endovascular Surgery, 2000